Introduction
Phosphoinositide-specific phospholipase C (PI-PLC) plays a key role in responses to a large number of extracellular signals. Three families of mammalian PI-PLC, PLCb, PLCg and PLCd, have been extensively characterized (Katan, 1998; Rebecchi and Pentyala, 2000; Rhee, 2001) . Several isoforms, encoded by different genes, comprise each family (PLCb1-4, PLCg1-2 and PLCd1, d3-4) while further molecular diversity is generated by splice variants derived from a single gene. More recently, new mammalian PI-PLC sequences have been reported that represent a distinct family; this PI-PLC has been designated as PLCe Lopez et al., 2001; Song et al., 2001) . Although two different human PLCe sequences have been identified (Lopez et al., 2001; Song et al., 2001) , their relationship was not clarified.
PLCe, in common with other PI-PLC families, incorporates the PLC catalytic domain and C2 domain Lopez et al., 2001; Song et al., 2001) ; the presence of the PH domain and EF-hands has also been suggested (Wing et al., 2001) . Within the unique regions, PLCe has CDC25 guanine exchange factor (CDC25 GEF) domain and two Ras-association or Rasbinding (RA/RBD) domains Lopez et al., 2001; Song et al., 2001) . Further studies have suggested that CDC25 GEF could function as an exchange factor (Jin et al., 2001) , while studies of RA/ RBD domains have shown direct interaction with several Ras family members in GTP-bound form Song et al., 2001 Song et al., , 2002 . In some of the studies, it was also shown that PI-PLC activity of PLCe can be stimulated by activated Ras when both molecules were introduced into COS cells Song et al., 2002) . An increase in substrate hydrolysis by PLCe in transfected cells have been observed after stimulation by diverse stimuli including epidermal growth factor (EGF), lysophosphatic acid (LPA), sphingosine-1-phosphate (S1P), adrenalin and acetycholine (Schmidt et al., 2001; Evellin et al., 2002; Kelley et al., 2004) . Furthermore, these and other studies suggest that signaling pathways triggered by these agonists could be quite broad and in some cases independent of Ras family GTP-ases (Lopez et al., 2001; Wing et al., 2001 Wing et al., , 2003 Kelley et al., 2004) . However, regarding that most approaches involved overexpression of PLCe, it still remains to be established which of the possible regulatory interactions are physiologically relevant. It also remains unclear whether potential diversity of PLCe molecules (Lopez et al., 2001; Song et al., 2001) could underlie some of this diversity in signaling.
The studies focusing on PLCe interaction with Ras demonstrated that PLCe fulfills most criteria to be considered as an effector of Ras Song et al., 2001) . Other Ras effectors containing RA/ RBD domain include Raf protein kinases, phosphatidylinositol 3-kinase (PI3-K) isoforms, guanylnucleotide exchange factors active on the Ral A (RalGDS and related molecules) and several smaller proteins without enzyme activity (e.g. AF-6 and NORE/RASSF) (Cox and Der, 2003; Downward, 2003) . Since the activated form of Ras has been associated with B20% of human tumors, many studies have addressed the questions as to how interactions with different effectors could underlie different Ras-mediated cellular responses and how these interactions could contribute to tumoroginesis. However, the emerging picture is rather complex and selection of a distinct effector confers the outcome only in part. Nevertheless, Raf/MAP kinase pathway has in many cases been associated with Ras-mediated cell-cycle progression and transcription, PI-3K with survival, cytoskeletal signals and transcription while NORE/ RASSF proteins seem to be involved in apoptotic effects of Ras. Involvement of different effectors in cancer-related processes, through mutations and changes in levels of expression, has also been analysed and supported importance of specific pathways in tumorigenesis (Shayesteh et al., 1999; Davies et al., 2002; Pfeifer et al., 2002; Hesson et al., 2003) . In case of PLCe, this type of study has not been performed.
In this study we first clarified that two previously identified sequences of PLCe correspond to splice variants generated from a single PLCe gene. Further comparative analysis of these splice variants demonstrated similarities in signaling properties and suggested that both splice variants could function as an effector of Ras. Analysis of expression of two splice variants in normal tissues, established cell lines and tumor tissues revealed their distinct distribution and downregulation in colorectal tumors. In addition, the data obtained in colorectal cell lines suggested the possibility of epigenetic silencing and inhibitory effects of PLCe when re-introduced to those cells.
Results

Splice variants of PLCe and their expression
In contrast to other PI-PLCs where several genes have been described for each family, the analysis of available genomes failed to identify related genes that would belong to PLCe family. The alignment of the human genomic sequence and the published cDNA sequences (Lopez et al., 2001; Song et al., 2001 ) strongly suggests that they correspond to splice variants arising from a single gene, PLCe1 (Figure 1a ). This prediction was confirmed by PCR analysis and Northern blotting, demonstrating alternative splicing of exons 1 and 2 to exon 3 (Figure 1b) . Comparison of two cell lines (HEK293T and HEK293A) used for this analysis also suggested their different expression with the first splice variant expressed in both cell lines and the second only in HEK293T. According to the nomenclature that has been applied to other PI-PLC splice variants, we designated the first and second splice variant as PLCe1a and PLCe1b.
Although initial studies of PLCe mRNA expression Lopez et al., 2001) have indicated broad tissue distribution, they could not distinguish between the splice variants. Using specific primers, expression of PLCe1a and PLCe1b mRNA was analysed in a panel of tissues and cell lines (Figure 1c ). PLCe1a and PLCe1b had different tissue distribution ( Figure 1c , top); PLCe1a was more broadly expressed and only absent in peripheral blood leukocytes, while PLCe1b could not be detected in peripheral blood leukocytes, skeletal muscle, thymus and testis and was enriched in placenta, lung and spleen. Analysis of different mouse tissues for protein expression confirmed broad expression of PLCe. However, it was difficult to unequivocally identify slightly smaller PLCe1b and distinguish it from possible degradation product of PLCe1a (data not shown). Analysis of cell lines (Figure 1c, bottom) showed that PLCe is not expressed as broadly as in tissues. In addition to cell lines of haematopoietic origin (EBV and Jurkat) neither PLCe could be detected in HeLa, A431 or MCF7 cell lines. The difference between expression of PLCe1a and PLCe1b in cell lines was even more striking than in tissues. While PLCe1a was expressed in all cell lines where PCR product from the common region could be detected, PLCe1b mRNA was only expressed in HEK293T cells. These data suggest that PLCe expression in cell lines is more restricted and that majority of the cell lines express only PLCe1a. To analyse expression of PLCe1a protein in different cell lines, the protein was first enriched by 'pull down' using H-Ras and then visualized by Western blotting. As described in more detail for another panel of cell lines, this demonstrated restricted protein expression that correlated with the presence of PLCe1a mRNA (Figure 5a ).
Signaling properties and subcellular localization of PLCe1a and PLCe1b
While the independent studies of PLCe corresponding to PLCe1a and PLCe1b demonstrated some similarities, they also pointed out potential differences in the type of agonist capable of PLCe stimulation (Evellin et al., 2002; Schmidt et al., 2001; Kelley et al., 2004) . In addition, significant differences could exist regarding the ability of H-Ras to stimulate these two forms Lopez et al., 2001) . While some of the differences observed could be due to differences between PLCe1a and PLCe1b, some could also result from differences in the experimental systems used in these independent studies.
To assess whether PLCe1a and PLCe1b have properties that could determine differences in signaling functions, the two splice variants were expressed in COS cells and PI-PLC activity towards the cellular substrate analysed. In the absence of an extracellular signal, basal activity of PLCe1b was consistently higher when expressed at a comparable protein level to PLCe1a (Figure 2a ). PI-PLC activity of both splice variants can be further stimulated after addition of S1P or, even more potently, EGF, which resulted in four-to five-fold increase of substrate hydrolysis (Figure 2a ). Based on several independent experiments, stimulation (Btwofold) was observed after cotransfection with an activated form of H-Ras (V12) both for PLCe1a and PLCe1b (Figure 2a) . The ability of PLCe1a and PLCe1b to .33) and prediction of two mRNA splice variants (PLCe1a and PLCe1b). Numbers (bp) corresponding to boundaries of exon 1, exon 2 and the region encompassing start of exon 3 to the end of exon 32, were according to Ensembl (EBI, Sanger Institute). (b) Total RNA from HEK293A and HEK293T was extracted and subjected to RT-PCR using primers for the indicated exon combinations (left panel). PolyA þ RNA from HEK293A and HEK293T cells was analysed by Northern blotting using probes specific for PLCe1a (exon 1), PLCe1b (exon 2) or common for both (exons 4/6) splice variants (right panel). (c) cDNA samples from various human tissues (top) and cell lines (bottom) were subjected to RT-PCR analysis using primers specific for PLCe1a (exon 1/3), PLCe1b (exon 2/3) or both splice variants (exon 6/8). PCR products for GAPDH, one of four of ubiquitously expressed molecules used to normalize the samples, are also shown interact with H-Ras was demonstrated further using HRas to 'pulldown' PLCe1a and PLCe1b from extracts of transfected cells; both splice variants were present in complexes with H-Ras when loaded with GTP ( Figure 2b ). Using larger amounts of cellular extracts of nontransfected cells, interaction of endogenous PLCe with immobilized H-Ras was also shown ( Figure 2c) ; the requirement for larger amounts of the extract in this case could be due to relatively low levels of endogenous protein combined with moderate affinity and a possibility that not all endogenous PLCe could be accessible for the interaction with Ras. Thus, the data obtained from the direct comparison of PLCe1a and PLCe1b in the presence of different extracellular signals or activated HRas demonstrate potential of both splice variants to contribute to cellular responses in normal and Rastransformed cells.
Next, we explored the possibility that unique sequences could be involved in determining subcellular localization. Since the localization of PLCe endogenously present in cells has not been studied, we first analysed different cell types using several anti-PLCe antibodies to the common region. The protein was more readily detected in primary cells (data not shown), and further analysis obtained using primary cardiac myocytes and two different antibodies suitable for immunostaining. They both revealed strong perinuclear staining, similar to a Golgi protein (58K), and a less pronounced distribution throughout the cytoplasm (Figure 3a) . A similar distribution was observed after expression of PLCe1a or PLCe1b in different cell types, with the area around the nucleus increasing with higher levels of expression of either of the splice variants in cardiac myocytes and COS cells (Figure 3b and c). This study of subcellular localization have shown that endogenous PLCe is present in specific regions that may be distinct from localization of other PI-PLC families (Katan, 1998; Rebecchi and Pentyala, 2000; Rhee, 2001) . Also, the data suggest that both splice variants could contain determinants for this localization implying that variable regions at the N-terminus are not likely to govern this localization. In addition, in transfected COS cells that show perinuclear staining, some redistribution of PLCe was seen after stimulation by EGF with a fraction of PLCe1a and PLCe1b localizing at the plasma membrane (Figure 3c ).
Expression of PLCe1a and PLCe1b in cancer tissues
Since previously published Song et al., 2001 ) and data in Figure 2 support function of PLCe as an effector of Ras, further analysis of PLCe Figure 2 Signaling properties of PLCe1a and PLCe1b. (a) COS-7 cells, transfected with the control plasmid (white bars), PLCe1a (hatched bars) or PLCe1b (black bars), were either left unstimulated (None) or stimulated with S1P or EGF for 60 min as described in Materials and methods. For all plasmids, cotranfection with H-Ras V12 was also performed. PLC activity is expressed as the total inositol phosphates (IP) formed relative to the amount of [ 3 H]myo-inositol in the phospholipid pool. The level of expression of PLCe1a and PLCe1b, when transfected on their own (top left) or cotransfected with H-Ras (top right) was analysed by Western blotting using antibody to the common region (CS117). As a control, PLCg1 was analysed using a specific antibody to this isoform (middle). The expression levels of tranfected H-Ras were also analysed using anti-H-Ras antibodies (bottom right). (b) HEK293T cells were transfected with PLCe1a, PLCe1b or CRaf plasmids. Cell extracts were subjected to pull down with GST-H-Ras loaded with either GDP (lane 1) or GTP (lane 2) and the presence of PLCe1a, PLCe1b or CRaf analysed by Western blotting. Amounts of preloaded GST-H-Ras protein in pull downs were also analysed (lower panels). (c) A cell extract from non-transfected HEK293T cells, containing larger amounts of protein (25 mg), was subjected to pulldown using equal molar amounts of GST (1) and GST-HRas preloaded with GTP-g-S (2), as described in Materials and methods. Endogenous PLCe and CRaf were detected in the pull down using two anti-PLCe (CS117 and CV221) and an anti-Raf antibodies, respectively PLCe splice variants in signaling and cancer SC Sorli et al expression was performed using an array of matched pairs from normal and tumor tissues. Using hybridization probes corresponding to the common region, the best signal was detected in samples generated from colon and rectum (data not shown). Further analysis after standardization to ubiquitin demonstrated reduced expression of PLCe mRNA in tumor samples from both selected tissues (Figure 4a and b) . A total of 28 matched pairs from colon and 18 pairs from rectum were analysed. In colon samples, B64% of the pairs showed reduction, B33% was within two-fold difference and considered as 'no change', while B2% showed an increase. Similarly, a comparison of pairs derived from rectum revealed reduction in B84% of pairs, while B16 % was within two-fold difference. A decrease of up to 10-fold was observed. To confirm observations using hybridization probes, samples from some of the matched pairs were analysed by PCR using common primers and primers specific for the two splice variants.
As shown in Figure 4c for one pair from the colon panel, the PCR analysis confirmed reduction of PLCe expression in tumor tissue. Analysis of expression of PLCe1a and PLCe1b for the same pair demonstrated reduction of PLCe1a expression in the tumor sample while PLCe1b could not be detected in normal tissue (Figure 4c) . Very low levels of PLCe1b were detected only in normal tissue of another colon pair (data not shown). These data suggest that expression of PLCe could be at lower levels in tumor compared to normal colon and rectal tissues. Although this is more clearly demonstrated for PLCe1a, expression of both splice variants could be reduced. Hybridization with a PLCe1 common probe (PLCe) was carried out first (left panels); the same array was stripped and hybridized with a probe to ubiquitin (Ub) (right panels). (b) The ratios between standardized samples for each N/T pair was calculated and the data expressed as a fold decrease or fold increase. (c) Semiquantitative PCR using cDNA from one of the colon N/T pairs (pair 2) was carried out to amplify common region of PLCe1 (left panels) and regions specific for PLCe1a or PLCe1b (right panels) including HEK293T cells as a control (c). S9 ribosomal protein was also amplified 
Analysis PLCe in colorectal tumor cell lines
To obtain further insight into the role that PLCe could have in colorectal tissue, a panel of cell lines derived from colorectal tumors was analysed for expression of PLCe (Figure 5a ). Only PLCe1a mRNA was detected in several cell lines but was below detection under the same experimental conditions in SW260 and SW480 cells. In agreement with the mRNA expression, PLCe1a protein could not be detected in SW260 and SW480 cells while in two cell lines expressing PLCe1a mRNA (HT29 and HCT116) the protein was also detected.
One of the possibilities that have been explored using the cell lines with substantially reduced or lacking PLCe expression was epigenetic regulation of gene expression (Figure 5b) . When an inhibitor of DNA methylation (5-aza-2 0 deoxycytidine) was used, levels of expression of PLCe and, specifically, PLCe1a splice variant increased and were clearly detectable even when low number of PCR cycles was used for the analysis (top panels). While PLCe1b could not be detected in untreated cells even after large PCR amplification, the treatment with 5-aza-2 0 deoxycytidine resulted in substantial expression of PLCe1b mRNA (bottom panel). These data suggest that, at least in some tumor cells, downregulation of PLCe could be a consequence of DNA hypermethylation.
We also analysed effects of exogenous expression of PLCe in cell lines with substantially reduced or lacking PLCe expression. The data obtained using SW480 cells microinjected with PLCe constructs or the control plasmids are shown in Figure 6 . Cells expressing PLCe proteins and the control cells were analysed using realtime imaging and the events of cell divisions and cell death quantified. During the recording, the number of cells expressing PLCe splice variants (green fluorescence) was reduced; this is illustrated for PLCe1a by representative fields of cells at the selected time points (Figure 6a, top panel) . In contrast, cells expressing control protein (green florescent tag only) increased in number during the recording (Figure 6a , bottom panel). As summarized in Figure 6b , cells expressing PLCe1a or PLCe1b showed reduction in cell proliferation (left) and an increase in cell death events (right). These effects were reduced by PI-PLC inactivating mutations (Figure 6b ), where critical catalytic residues (Ellis et al., 1998) were mutated generating an enzyme nonresponsive to EGF stimulation (control ¼ 12.273%, wild type ¼ 4275% and mutant ¼ 14.772%). The ratio of cell death/mitosis was enhanced in the absence of serum; under these conditions the effect was similarly reduced by PI-PLC inactivating mutation (data not shown).
Discussion
In the present study we first demonstrate that the molecular diversity in PLCe family arises from alternative splicing. Identification of two splice variants (Figure 1 ) was followed by comparative analysis regarding signaling, localization and tissue and cell distribution (Figures 1-3 ). Splice variants encoded by a single PI-PLC gene have been described for several isoforms from PLCb and PLCd families (Rebecchi and Pentyala, 2000) . Structurally, differences introduced by alternative splicing vary a great deal and occur within different domains of PI-PLC. In PLCe1 it is the Nterminus of the molecule that contains unique sequences (Figure 1 ) similarly as suggested for PLCb4 (Alvarez et al., 1995) . Functional differences also vary from a loss of PI-PLC activity (Nagano et al., 1999) to changes in 0 -aza-2-deoxycytidine ( þ AZA) or left untreated (ÀAZA). After 3 days, RNA was extracted and RT-PCR performed. Number of cycles is indicated for PLCe common region and PLCe1a (top panels) while the data for PLCe1b (bottom panels) show amplification after 34 cycles. HEK293T sample (293T) and no templates (/) were included as controls; GAPDH was amplified to verify loading signaling and localization (Kim et al., 1998) . Differences in tissue distribution have been reported for most splice variant-subtypes (Rebecchi and Pentyala, 2000) . Work described here shows that PLCe splice variants also have differences in tissues and, in particular, distribution in cell lines; PLCe1a has been identified in all tissues and cells expressing PLCe while PLCe1b mRNA has more restricted expression and is absent from a variety of cell lines (Figure 1) . The possibility that transcription of two splice variants could involve different components adds complexity and versatility to the control of gene expression, suggesting that this could be an important level of PLCe regulation.
Since the molecules shown here to be splice variants of PLCe have been reported and analysed separately (Lopez et al., 2001; Song et al., 2001) , our data have established a relationship between these PLCe entities and provided the first direct comparison of their regulatory properties. From the separate studies it was not possible to conclude whether different signaling pathways involve distinct forms of PLCe and the data presented here (Figure 2 ) suggest that this may not be the case. Specifically, we demonstrate that PLCe1b can be, like PLCe1a, stimulated through G-protein coupled receptors such as S1P receptor as well as tyrosine kinase, EGF receptor (Figure 2) . The data from comparison of the splice variants also show similar stimulation of PI-PLC activity by H-Ras and the ability to interact with its GTP-bound form, as found here for endogenously expressed PLCe (Figure 2) . Thus, both splice variants Figure 6 Effects of PLCe expression on cell viability. SW480 cells in 10% serum were microinjected with different PLCe plasmids and monitored by video time-lapse microscopy. (a) Cells microinjected with plasmids coding for GFP-PLCe1a (top panels) or GFP-tag only (bottom panels). Green fluorescence was visualized in green and phase contrast in red. (b) Quantification of cell mitosis (left) and cell death (right) events was performed for GFP (1), GFP-PLCe1b (2), GFP-PLCe1a (3) and GFP-PLCe1a catalytically inactive (CI) (His1407Ala/Asn1408Ala) mutant (4) expressing cells as described in Materials and methods. The data are representative of three independent experiments should be considered as effectors of Ras. The similarity is further reinforced by observations that both splice variants could localize to the perinuclear region, as shown for the endogenous PLCe, and that in response to EGF stimulation both could translocate to the plasma membrane (Figure 3) . However, despite shared potential to respond to same agonists, some differences in signaling responses could exist. For example, higher basal activity and higher overall activity after stimulation (e.g. EGF) has been observed for PLCe1b (Figure 2) . It is possible that this difference reflects stronger intramolecular constraint imposed by the unique region in PLCe1a and that it could affect function of the two splice variants in a physiological context.
Involvement of PLC isoforms in cancer-related processes have been suggested by several studies (Wells, 2000) ; however, systematic analysis of expression in tumors or the presence of mutations has not been performed for any of PI-PLC molecules. Although it is not clear how many different regulatory mechanisms control PLCe within the physiological context, PLCe seem to be linked to Ras GTP-ases as their effector Song et al., 2001) and through its CDC25 GEF activity (Jin et al., 2001) . Since the importance of Ras pathway in tumor development has been extensively documented, mutations and changes in expression levels have been analysed for Ras as well as upstream and downstream components (Cox and Der, 2003; Downward, 2003) . In addition to activating mutations in H-N-and K-Ras, activating mutations have been also found in BRaf (Davies et al., 2002; Downward, 2003) . It has also been described that levels of expression of another Ras effector, PI-3K, are upregulated by gene amplification in some ovarian tumors (Shayesteh et al., 1999) . In contrast, proteins from NORE/RASSF family, likely to have tumor suppressor function, are downregulated or absent from several tumor types (Pfeifer et al., 2002; Hesson et al., 2003) . The analysis of PLCe in normal and tumor tissues (Figure 4) suggests downregulation of mRNA expression in colorectal tumors. Furthermore, at least in some colorectal cell lines, the expression of PLCe1a and PLCe1b can be restored in the presence of an inhibitor of DNA methylation (Figure 5 ), suggesting that hypermethylation of PLCe gene or genes essential for its transcription could lead to epigenetic silencing. This mechanism, where promoter region containing CpG islands becomes hypermethylated, has been described in many tumor types (with most originating from the gastrointestinal tract) and results in inactivation of diverse cellular processes including DNA repair, cell cycle, cell adherence, hormonal responses and apoptosis (Esteller, 2003; Jaenisch and Bird, 2003) . In the case of a NORE/RASSF family member, Rassf1A, the hypermethylation occurs in a variety of tumors (Pfeifer et al., 2002) . As expected from its tumor suppressor role and consistent with the suggestion of a selective advantage due to its loss in cancer, the reintroduction of RASSF/ NORE molecules into tumor cells, an expression in some others cell types, has an inhibitory effect by promoting cell cycle arrest and apoptosis (Vos et al., 2003a, b) . Similar to observations with RASSF/NORE, we also show that exogenous expression of PLCe in colorectal tumor cells results in higher cell death and inhibition of proliferation ( Figure 6 ). Based on previously published data (Song et al., 2002 ) and our observations (not shown), this is not a general property of PLCe when introduced to various cell types. However, it remains to be established whether the ability of PLCe to be integrated into different pathways in various cell types determines these different cellular responses. Nevertheless, data shown here (Figures 5 and  6 ) support epigenetic downregulation of PLCe in some cancer cells and potential of PLCe to negatively regulate viability and proliferation of those cells.
Materials and methods
Cell lines, DNA constructs and antibodies COS-7, HEK293A, HEK293T, HT29, HCT116, SW480, SW620, LOVO and MAWI cell lines were cultured in DMEM with 10% FBS. Human colorectal and adenoma-derived cell lines RGC2, AAC1 and AAC1/SB/10 were cultured as described (Guy et al., 2001) . Rat cardiac myocytes from hearts of 3-day-old rats were cultured as described previously (Bogoyevitch et al., 1995) .
Construct incorporating larger form of human PLCe without tag sequences was generated from pcDNA3.1GFP-PLCe by excising GFP sequence with NotI. The inactivating catalytic mutations, His1407Ala/Asn1408Ala double mutant, were introduced into pcDNA3.1GFP-PLCe using site-directed mutagenesis kit (Stratagene). Another plasmid, pCMVPLCe-Flag, encoding larger form of rat PLCe has been described . Smaller form of human PLCe without tag sequences was generated from pCMVmycPLCe plasmid (Lopez et al., 2001) . Briefly, a PCR fragment encompassing unique sequences for the smaller form was amplified using pCMVmycPLCe, with a forward primer containing NotI site. The PCR fragment, digested with NotI and Bsu36I was inserted into pcDNA3.1GFP-PLCe cut by NotI and Bsu36I. A similar strategy, using the same restriction sites, was used to generate pcDNA3.1GFP-PLCe construct of the smaller form.
Plasmids encoding activated form of H-Ras were pTriEx4H-RasV12, generated by PCR and Ek/LIC cloning of the ORF of Ras into vector pTriEx4 (Novagen), and previously described pGex2THRasV12 (Marais et al., 1995) . The pEFmyCRaf plasmid, encoding human CRaf, was described previously (Chiloeches et al., 2001) .
Two PLCe antipeptide polyclonal rabbit antibodies (CS117 against CSDDNILEDRPENKSC and CV221 against CVKDTTNKKTTTPKSSC) were generated. After purification of total IgG from the antisera, further purification was achieved using the Actigel ALD affinity resin (Sterogene) with the conjugated peptides. Another antibody against PLCe (TK3) has been described previously (Wu et al., 2003) . These three antibodies against PLCe recognize different regions of this protein (CS117 recognizes a loop in the catalytic domain that is variable among PI-PLC isoforms, CV221 the RA2 domain and TK3 the C-terminus) and were compared for their abilities to recognize expressed human and rat PLCe by Western blotting and immunostaining. Based on this analysis CS117 and CV221 were preferentially used for Westen blotting while CS117 and TK3 were used for immunostaining.
Other antibodies used were anti-Raf (Anogen), anti-myc 9E10 (ICR), anti-FLAG (Sigma) and anti-Golgi 58K protein (Sigma); secondary antibodies were from Jackson Stratech.
Isolation of RNA, reverse transcription-PCR and Northern blotting
Total RNA was extracted using RNABee (Biogenesis) and cDNA samples were generated using 5 mg of total RNA and ImProm-IIt Reverse Transcriptase (Promega). Additional panel of cDNA samples from tissues and cell lines was obtained from Clonthech BD Biosciences. These cDNA samples were normalized using four ubiquitously expressed molecules: a-tubulin, b-actin, GAPDH and phospholipase A2. PCR reactions, containing various cDNA tamplates (0.2 ng/ ml), were carried out with TaqDNA polymerase (Qiagen). All PCR products of predicted sizes were cloned into pGEM s -T easy vector (Promega) to enable sequencing and confirm fully their identity.
PolyA þ RNA was purified from total RNA, using MicroPoly(A)Puristt Purification Kit (Ambion), and Northern blotting was performed using NorthernMaxt Kit (Ambion). Briefly, 10 mg of polyA þ RNA from HEK293A and HEK293T cells was subjected to electrophoresis on a 1% agarose gel, RNA was transferred onto a nylon membrane (BrightStart-Plus-Ambion) and incubation was carried out with [a-32 P]dCTP radiolabeled DNA probes synthesized using Megaprimet DNA labeling system (Amersham Pharmacia). To produce a template for the probes, PCR products were generated from exons 1, 2 and 4-6, 280 bp each.
Cancer profiling array
Cancer profiling array I (Clontech BD Biosciences) was hybridized with radiolabeled DNA probes according to the manufacturer's instructions.
32 P-radiolabeled DNA probes were synthesized using the same method as for Northern blotting. PCR product specific for PLCe (B1.2 kb) that gave the best signal was generated using CATGTATCAGAAG TTTTCTCC (sense) and CTGAGAAGGTGATGTAAGTC (antisense) primers. Template for ubiquitin probe was provided with the array. In total, 20 Â 10 6 cpm of the probes was used for 16 h hybridization at 681C. RNA expression was quantified using a phosphorimager (Molecular Dynamics). Values for PLCe were normalized to values for ubiquitin.
Transfection of COS cells and measurements of PLC activity
In total, 2.5 Â 10 5 COS cells were seeded into six-well plates and transfected with 0.5-2 mg of plasmid encoding PLCe and/ or activated H-Ras, using LipofectAMINE Plus (Invitrogen). For measurements of PLC activity (based on Berridge et al., 1989) , the cells were labeled with 2 mCi/ml of myo-[2-3 H]Inositol (Amersham Pharmacia) for 24 h. The stimulation was with 100 ng/ml of EGF (Sigma) or 0.5 mM S1P (Avanti Polar Lipids) in the presence of 20 mM LiCl as previously described (Kelley et al., 2004) . After the incubation at 371C for 60 min, the reaction was quenched by 4.5% perchloric acid (PCA) and incubation continued on ice for 30 min. Cells were scraped and proteins/lipids were pelleted by centrifugation, while supernatants were neutralized and inositol phosphates were purified using AG1-X8 200-400 columns (BioRad). Lipid extraction was performed from PCA pellets by the addition of chloroform : methanol : HCl (100 : 200 : 15) and isolation of the chloroform phase. Radioactivity in fractions containing inositol-phosphates and lipids was determined by scintillation counting. In this assay, essentially the same data for PLC activity were obtained for a specific PLCe form, regardless of the presence of a tag or origin (human or rat).
Isolation of PLCe proteins through interaction with immobilized H-Ras
Protein extracts were generated from nontransfected colorectal cancer cell lines and HEK293T cells as well as from HEK293T transfected with PLCe constructs or a construct encoding CRaf. The cells were resuspended in lysis buffer (25 mM Tris HCl pH 7.5, 1 mM EDTA, 0.1% Triton X-100, 1 mM DTT, protease inhibitors), sonicated briefly and incubated on ice for 30 min and the extracts obtained after centrifugation at 14 000 g for 10 min. The extracts (5-25 mg of protein) were combined with 9 mmol of GST or GST/H-Ras (V12) bound to glutathione Sepharose 4B (Amersham Pharmacia); GST/HRas (V12) was preloaded with GDPbS or GTPgS. The incubation was carried out overnight in a buffer containing 50 mM Tris HCl pH 7.5, 150 mM NaCl, 1 mM DTT, 1% Triton X-100, 2 mg/ml BSA and 12.5 mM MgCl 2 . The pellet obtained after centrifugation for 5 min at 1.200 r.p.m. was washed and proteins visualized by Western blotting using anti-PLCe, antiRaf or anti-tag (Myc or FLAG) antibodies.
Microinjection, immunofluorescence and time-lapse microscopy
Plasmids were microinjected at a concentration of 50 mg/ml for various PLCe constructs or 0.5 mg/ml for GFP. The immunofluorescence analysis was performed 6-16 h after microinjection using anti-PLCe or anti-tag primary antibodies (10 mg/ml) and appropriate secondary antibodies. In all, 1 : 20 dilution of CS117 antibody was used to visualize endogenous protein and 1 : 100 for the expressed splice variants. Cells were viewed using a Bio-Rad MRC 1024 microscope. In studies of subcellular localization, essentially the same data were obtained for PLCe forms, regardless of the presence, type and position of a tag; this was confirmed using nontagged versions (described in Results) or with C-terminal FLAG tag or with N-terminal GFP tag for the long form and N-terminal Myc-tag or N-terminal GFP tag for the short form.
Alternatively, microinjected cells were analysed by timelapse video microscopy recording phase contrast and GFP fluorescence using a Nikon Diaphot inverted fluorescence microscope with environmental chamber, equipped with a Hamamtsu Orca-ER digital camera, by C-imaging 'Simple PCI' image capture and processing software. About 100 cells were microinjected with each plasmid, the protein expression in these cells monitored by green fluorescence and the recording was carried out for 48 h. Based on analysis of phase contrast and GFP fluorescence recordings for morphological changes, together with TO-PRO-3 staining (Pyrzynska et al., 2002) , the events of cell divisions and cell death were calculated using the following formulas: % mitosis ¼ (m/n)100 and % death ¼ [d/(m þ n)]100 (where m is the mitosis, n is the number of green cells at the beginning and d is the death event). For each GFP-PLCe construct and experimental condition, GFP has been included as a control and microinjected into cells in a separate field of the same dish.
